Eurofins Scientific SEERFSF +0.21%79 Cash Ratio is 0.33 as of Dec. 2025, which is 3% below its 10-year median of 0.34. GuruFocus rates ERFSF with a GF Score™ of 79/100 and a GF Value™ of $78.22 (Fairly Valued). The stock has 7 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 75.12% on this metric.
Eurofins Scientific SE has a Cash Ratio of 0.33. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Eurofins Scientific SE's Cash Ratio or its related term are showing as below:
ERFSF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.19 Med: 0.34 Max: 1.16
Current: 0.33
During the past 13 years, Eurofins Scientific SE's highest Cash Ratio was 1.16. The lowest was 0.19. And the median was 0.34.
ERFSF's Cash Ratio is ranked worse than 75.12% of 209
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.96
vs ERFSF: 0.33
Eurofins Scientific SE (OTCPK:ERFSF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a Cash Ratio of 0.33 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Eurofins Scientific SE and its competitors. This is near median its historical median of 0.34. Over the past decade, Eurofins Scientific SE's Cash Ratio has ranged from 0.19 to 1.16. According to the industry distribution chart, Eurofins Scientific SE ranks #157 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 75.1%.
Is Eurofins Scientific SE's Cash Ratio too high?
Eurofins Scientific SE's current Cash Ratio of 0.33 is near median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 1.16. The Medical Diagnostics & Research industry median Cash Ratio is 0.96. Eurofins Scientific SE's value of 0.33 is 65.6% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #157 out of 209 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Eurofins Scientific SE has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #157 out of 209 companies for Cash Ratio. This places Eurofins Scientific SE in the lower half of its industry. The industry median Cash Ratio is 0.96. Eurofins Scientific SE's value of 0.33 is 65.6% below this benchmark. Historically, Eurofins Scientific SE's own Cash Ratio has ranged from 0.19 to 1.16 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 0.96, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.96, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current Cash Ratio of 0.33 is 65.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current Cash Ratio is 0.33, which is near median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $78.22, compared to a current price of $80.40 — trading 2.8% above its estimated fair value. The current Cash Ratio is 0.33, which is near median its 10-year median of 0.34 and 65.6% below the Medical Diagnostics & Research industry median of 0.96. Eurofins Scientific SE's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Cash Ratio is 0.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $80.40 is trading 2.8% above its estimated GF Value™ of $78.22.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
Cash Ratio: 0.33 (near median its 10-year median of 0.34)
GF Value™: $78.22 vs. price of $80.40 (2.8% above fair value)
Industry Position: 65.6% below the Medical Diagnostics & Research median (#157 of 209)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
79GF Score
Get the complete analysis for ERFSF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
